Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma.

Marko TA, Shamsan GA, Edwards EN, Hazelton PE, Rathe SK, Cornax I, Overn PR, Varshney J, Diessner BJ, Moriarity BS, O'Sullivan MG, Odde DJ, Largaespada DA.  Sci Rep. 2016 Dec 14;6:39059. doi: 10.1038/srep39059.

Heterotypic models of osteosarcoma recapitulate tumor heterogeneity and biological behavior.

Scott MC, Tomiyasu H, Garbe JR, Cornax I, Amaya C, O'Sullivan MG, Subramanian S, Bryan BA, Modiano JF.
Dis Model Mech. 2016 Nov 3. pii: dmm.026849. [Epub ahead of print] 

MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.

Fenger JM, Roberts RD, Iwenofu OH, Bear MD, Zhang X, Couto JI, Modiano JF, Kisseberth WC, London CA.
BMC Cancer. 2016 Oct 10;16(1):784. 

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.

Lagmay JP, Krailo MD, Dang H, Kim A, Hawkins DS, Beaty O 3rd, Widemann BC, Zwerdling T, Bomgaars L, Langevin AM, Grier HE, Weigel B, Blaney SM, Gorlick R, Janeway KA.
J Clin Oncol. 2016 Sep 1;34(25):3031-8. doi: 10.1200/JCO.2015.65.5381. 

Imprinting defects in osteosarcoma: DNA- and chromatin-modifying drugs hold promise for osteosarcoma therapy.

Sarver AE, Subramanian S.
Epigenomics. 2016 Jul;8(7):885-8. doi: 10.2217/epi-2016-0046. 

Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison.

Marko TA, Diessner BJ, Spector LG.
Pediatr Blood Cancer. 2016 Jun;63(6):1006-11. doi: 10.1002/pbc.25963.

Imprinting defects at human 14q32 locus alters gene expression and is associated with the pathobiology of osteosarcoma.

Shu J, Li L, Sarver AE, Pope EA, Varshney J, Thayanithy V, Spector L, Largaespada DA, Steer CJ, Subramanian S.
Oncotarget. 2016 Apr 19;7(16):21298-314. doi: 10.18632/oncotarget.6965. 

Aberrant Retinoblastoma (RB)-E2F Transcriptional Regulation Defines Molecular Phenotypes of Osteosarcoma.

Scott MC, Sarver AL, Tomiyasu H, Cornax I, Van Etten J, Varshney J, O'Sullivan MG, SubramanianS, Modiano JF.
J Biol Chem. 2015 Nov 20;290(47):28070-83. doi: 10.1074/jbc.M115.679696.

Coping with cancer genes altered by copy number.

Wolf NK, Largaespada DA, Moriarity BS.
Oncotarget. 2015 Nov 3;6(34):35155-6. doi: 10.18632/oncotarget.6215. No abstract available. 

A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma.

Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, Panagiotou OA, Largaespada D, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, de Toledo SR, Petrilli AS, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Andrulis IL, Wunder JS, Gokgoz N, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Halai D, Ballinger ML, Thomas DM, Davis S, Barkauskas DA, Marina N, Helman L, Otto GM, Becklin KL, Wolf NK, Weg MT, Tucker M, Wacholder S, Fraumeni JF Jr, Caporaso NE, Boland JF, Hicks BD, Vogt A, Burdett L, Yeager M, Hoover RN, Chanock SJ, Savage SA.
Cancer Discov. 2015 Sep;5(9):920-31. doi: 10.1158/2159-8290.CD-15-0125. 

A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis.

Moriarity BS, Otto GM, Rahrmann EP, Rathe SK, Wolf NK, Weg MT, Manlove LA, LaRue RS, Temiz NA, Molyneux SD, Choi K, Holly KJ, Sarver AL, Scott MC, Forster CL, Modiano JF, Khanna C, Hewitt SM, Khokha R, Yang Y, Gorlick R, Dyer MA, Largaespada DA.
Nat Genet. 2015 Jun;47(6):615-24. doi: 10.1038/ng.3293. Epub 2015 May 11.

MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics.

Varshney J, Subramanian S.
Front Mol Biosci. 2015 Jun 17;2:31. doi: 10.3389/fmolb.2015.00031. Review.

Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors.

Cannon CM, Pozniak J, Scott MC, Ito D, Gorden BH, Graef AJ, Modiano JF.
Vet Comp Oncol. 2015 Mar;13(1):48-59. doi: 10.1111/vco.12018.

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.

Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, Doyle LA, Chen H, Blaney SM.
Pediatr Blood Cancer. 2015 Mar;62(3):440-4. doi: 10.1002/pbc.25334.

Tumor-stromal cross talk: direct cell-to-cell transfer of oncogenic microRNAs via tunneling nanotubes.

Thayanithy V, Dickson EL, Steer C, Subramanian S, Lou E.
Transl Res. 2014 Nov;164(5):359-65. doi: 10.1016/j.trsl.2014.05.011.

Toward a drug development path that targets metastatic progression in osteosarcoma.

Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M.
Clin Cancer Res. 2014 Aug 15;20(16):4200-9. doi: 10.1158/1078-0432.CCR-13-2574.

Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.

Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S.
Pediatr Blood Cancer. 2014 May;61(5):833-9. doi: 10.1002/pbc.24874.  

Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.

Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, Krailo M, Villaluna D, Adamson PC, Blaney SM.
Pediatr Blood Cancer. 2014 Mar;61(3):452-6. doi: 10.1002/pbc.24605. 

Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.

London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, Wilson H, Jensen K, Ito D, Modiano JF, Bear MD, Pennell ML, Saint-Martin JR, McCauley D, Kauffman M, Shacham S.
PLoS One. 2014 Feb 4;9(2):e87585. doi: 10.1371/journal.pone.0087585.

A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).

Thompson PA, Drissi R, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, Ahern CH, Reid JM, Lin T, Weigel BJ, Blaney SM.
Clin Cancer Res. 2013 Dec 1;19(23):6578-84. doi: 10.1158/1078-0432.CCR-13-1117.

Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B.

Karlsson EK, Sigurdsson S, Ivansson E, Thomas R, Elvers I, Wright J, Howald C, Tonomura N, Perloski M, Swofford R, Biagi T, Fryc S, Anderson N, Courtay-Cahen C, Youell L, Ricketts SL, Mandlebaum S, Rivera P, von Euler H, Kisseberth WC, London CA, Lander ES, Couto G, Comstock K, Starkey MP, Modiano JF, Breen M, Lindblad-Toh K.
Genome Biol. 2013 Dec 12;14(12):R132. doi: 10.1186/gb-2013-14-12-r132. 

Genome-wide association study identifies two susceptibility loci for osteosarcoma.

Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Kurucu N, Ilhan IE, Sari N, Serra M, Hattinger C, Picci P, Spector LG, Barkauskas DA, Marina N, de Toledo SR, Petrilli AS, Amary MF, Halai D, Thomas DM, Douglass C, Meltzer PS, Jacobs K, Chung CC, Berndt SI, Purdue MP, Caporaso NE, Tucker M, Rothman N, Landi MT, Silverman DT, Kraft P, Hunter DJ, Malats N, Kogevinas M, Wacholder S, Troisi R, Helman L, Fraumeni JF Jr, Yeager M, Hoover RN, Chanock SJ.
Nat Genet. 2013 Jul;45(7):799-803. doi: 10.1038/ng.2645. 

Minnelide reduces tumor burden in preclinical models of osteosarcoma.

Banerjee S, Thayanithy V, Sangwan V, Mackenzie TN, Saluja AK, Subramanian S.
Cancer Lett. 2013 Jul 28;335(2):412-20. doi: 10.1016/j.canlet.2013.02.050. 

Human Wharton's jelly stem cell conditioned medium and cell-free lysate inhibit human osteosarcoma and mammary carcinoma cell growth in vitro and in xenograft mice.

Gauthaman K, Fong CY, Arularasu S, Subramanian A, Biswas A, Choolani M, Bongso A.
J Cell Biochem. 2013 Feb;114(2):366-77. doi: 10.1002/jcb.24367.

MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma.

Sarver AL, Thayanithy V, Scott MC, Cleton-Jansen AM, Hogendoorn PC, Modiano JF, SubramanianS.
Orphanet J Rare Dis. 2013 Jan 11;8:7. doi: 10.1186/1750-1172-8-7. 

Arginase treatment prevents the recovery of canine lymphoma and osteosarcoma cells resistant to the toxic effects of prolonged arginine deprivation.

Wells JW, Evans CH, Scott MC, Rütgen BC, O'Brien TD, Modiano JF, Cvetkovic G, Tepic S.
PLoS One. 2013;8(1):e54464. doi: 10.1371/journal.pone.0054464. 

The epidemiology of sarcoma.

Burningham Z, Hashibe M, Spector L, Schiffman JD.
Clin Sarcoma Res. 2012 Oct 4;2(1):14. doi: 10.1186/2045-3329-2-14. 

Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines.

Thayanithy V, Park C, Sarver AL, Kartha RV, Korpela DM, Graef AJ, Steer CJ, Modiano JF, Subramanian S.
PLoS One. 2012;7(9):e43720. doi: 10.1371/journal.pone.0043720. 

Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.

Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY, Chen HX, Krailo MD, Adamson PC, Blaney SM.
J Clin Oncol. 2012 Jan 20;30(3):256-62. doi: 10.1200/JCO.2011.37.4355.  

Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma.

Thayanithy V, Sarver AL, Kartha RV, Li L, Angstadt AY, Breen M, Steer CJ, Modiano JF, Subramanian S.
Bone. 2012 Jan;50(1):171-81. doi: 10.1016/j.bone.2011.10.012. 

Case-parent analysis of variation in pubertal hormone genes and pediatric osteosarcoma: a Children's Oncology Group (COG) study.

Musselman JR, Bergemann TL, Ross JA, Sklar C, Silverstein KA, Langer EK, Savage SA, Nagarajan R, Krailo M, Malkin D, Spector LG.
Int J Mol Epidemiol Genet. 2012;3(4):286-93./p>

Characterization of canine steosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart.

Angstadt AY, Motsinger-Reif A, Thomas R, Kisseberth WC, Guillermo Couto C, Duval DL, Nielsen DM, Modiano JF, Breen M.
Genes Chromosomes Cancer. 2011 Nov;50(11):859-74. doi: 10.1002/gcc.20908. 

Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach.

Scott MC, Sarver AL, Gavin KJ, Thayanithy V, Getzy DM, Newman RA, Cutter GR, Lindblad-Toh K, Kisseberth WC, Hunter LE, Subramanian S, Breen M, Modiano JF.
Bone. 2011 Sep;49(3):356-67. doi: 10.1016/j.bone.2011.05.008. 

Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma.

Tamburini BA, Phang TL, Fosmire SP, Scott MC, Trapp SC, Duckett MM, Robinson SR, Slansky JE, Sharkey LC, Cutter GR, Wojcieszyn JW, Bellgrau D, Gemmill RM, Hunter LE, Modiano JF.
BMC Cancer. 2010 Nov 9;10:619. doi: 10.1186/1471-2407-10-619./p>

Influence of genetic background on tumor karyotypes: evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma.

Thomas R, Wang HJ, Tsai PC, Langford CF, Fosmire SP, Jubala CM, Getzy DM, Cutter GR, Modiano JF, Breen M.
Chromosome Res. 2009;17(3):365-77. doi: 10.1007/s10577-009-9028-z.

Construction of a 2-Mb resolution BAC microarray for CGH analysis of canine tumors.

Thomas R, Scott A, Langford CF, Fosmire SP, Jubala CM, Lorentzen TD, Hitte C, Karlsson EK, Kirkness E, Ostrander EA, Galibert F, Lindblad-Toh K, Modiano JF, Breen M.
Genome Res. 2005 Dec;15(12):1831-7.

New paradigms for therapy for osteosarcoma.

Nagarajan R, Clohisy D, Weigel B.
Curr Oncol Rep. 2005 Nov;7(6):410-4. Review

Upper extremity limb salvage with microvascular reconstruction in patients with advanced sarcoma.

Kim JY, Subramanian V, Yousef A, Rogers BA, Robb GL, Chang DW.
Plast Reconstr Surg. 2004 Aug;114(2):400-8; discussion 409-10.

Osteosarcoma in the first decade of life.

Nagarajan R, Weigel BJ, Thompson RC, Perentesis JP.
Med Pediatr Oncol. 2003 Nov;41(5):480-3. No abstract available.

Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996).

Ehrhart N, Dernell WS, Hoffmann WE, Weigel RM, Powers BE, Withrow SJ.
J Am Vet Med Assoc. 1998 Oct 1;213(7):1002-6.